

Outpatient Drug Utilization Trends for Propoxyphene Products

**Hina Mehta, Pharm.D.
Drug Utilization Analyst
Division of Epidemiology
Office of Surveillance and Epidemiology
January 30, 2009**



**Anesthetic and Life Support Drugs and Drug Safety and
Risk Management Advisory Committees,
January 30, 2009**

Outline

- **Sales distribution analysis: IMS Health, IMS National Sales Perspectives™ Retail and Non-Retail**
- **Dispensed prescription and Patient-level analysis: SDI Vector One®: National (VONA) and SDI Total Patient Tracker (TPT)**
 - Propoxyphene products
 - Age distribution
 - Prescriber specialty
- **Summary**



Propoxyphene products included

- **Propoxyphene/APAP products:** Darvocet-N 100, propoxyphene-N/APAP, propoxyphene w/APAP, Balacet 325, Darvocet A500, Darvocet-N 50, Propacet 100, Wygesic, Trycet, Dolene AP-65, SK-65 APAP, Lorcet, Genagesic, E-Lor
- **Propoxyphene (single-ingredient):** propoxyphene, Darvon N, Darvon, Dolene Plain, SK-65, propoxyphene napsylate
- **Propoxyphene/Aspirin/Caffeine:** propoxyphene cpd, Darvon Compound-65, Dolene Compound-65, SK-65 Compound, Darvon Compound-32, Darvon Compound



Sales distribution data Year 2007

**IMS Health, IMS National Sales
Perspectives™ Retail and Non-Retail**



Anesthetic and Life Support Drugs and Drug Safety and
Risk Management Advisory Committees,
January 30, 2009


IMS Health, IMS National Sales Perspectives™

- Measures the volume of products, in units and dollars, moving from manufacturers to retail and non-retail channels of distribution
 - Eaches are the number of bottles, packets of pills, syringes, vials, etc. of a product shipped in each unit
- Retail Channels - chain, independent, mass merchandisers, food stores with pharmacies, and mail-order pharmacies
- Non-Retail Channels - federal facilities, non-federal hospitals, clinics, long-term care facilities, home health care (began 1998), HMOs, miscellaneous channels (began 1999; prisons, universities, other)



Projected number of packets of single ingredient and combination propoxyphene products sold from the manufacturer to retail and non-retail pharmacies in the U.S., Year 2007

IMS HEALTH, IMS National Sales Perspective™, Extracted 10/2008



- ▣ 90% of all propoxyphene sales as propoxyphene/APAP
 - Of which approximately 55% sold toward retail pharmacy channels

- ▣ 10% of all propoxyphene sales as single-ingredient propoxyphene
 - Approximately 80% of propoxyphene toward retail pharmacy channels

- ▣ 1% of all sales as propoxyphene/aspirin/caffeine
 - Of which approximately 60% sold toward retail pharmacy channels



Prescription and Patient-level Data

SDI Vector One[®]: National (VONA)

SDI Vector One[®]: Total Patient Tracker (TPT)



Anesthetic and Life Support Drugs and Drug Safety and
Risk Management Advisory Committees,
January 30, 2009

Surveillance Data, Inc.


Vector One[®]: National (VONA)

- **SDI's Vector One[®]: National (VONA) is a national-level projected prescription and patient-centric tracking service.**
 - **Receives over 2.0 billion prescription claims per year, representing over 160 million unique patients.**
- **The number of dispensed prescriptions is obtained from a sample of approximately 59,000 pharmacies throughout the U.S., accounting for nearly all retail pharmacies and represent nearly half of retail prescriptions dispensed nationwide.**
- **Retail pharmacies include:**
 - **national retail chains**
 - **mass merchandisers**
 - **pharmacy benefits managers and their data systems**
 - **provider groups**
- **Data on prescribing specialty and patient age/gender are available**



Total number of prescriptions dispensed for single-ingredient and combination propoxyphene from U.S. outpatient retail pharmacies, Years 1998 – 2007 and YTD/Oct 2008

SDI Vector One®: National (VONA), Extracted 12/2008




- Propoxyphene/APAP #1 dispensed propoxyphene product for the past 10 years however, it has been gradually decreasing (-26%) from Y1998 to Y2007
- Over 21 million dispensed prescriptions of propoxyphene/APAP during year 2007, accounting for over 97% of market



Total number of prescriptions dispensed for combination product propoxyphene/APAP by age from U.S. outpatient retail pharmacies, Years 2002- 2007 and YTD/Oct 2008

SDI Vector One®: National (VONA), Extracted 12/2008




- Elderly aged 65 years and greater: 8.3 million (38%) retail Rx in Y2007
- Adults aged 45-64 years: 8.2 million (38%) retail Rx in Y2007
- Adults ages 18-44 years: 5 million (23%) retail Rx in Y2007



Total number of patients receiving a prescription for single-ingredient and combination propoxyphene products from U.S. outpatient retail pharmacies, Years 2002 – 2007 and YTD/Oct 2008

SDI Vector One®: Total Patient Tracker (TPT). Extracted 1/2009




- Majority (~9.7 million Y2007) of patients received a prescription for propoxyphene/APAP
- 182,312 patients and 367 patients received a prescription for single ingredient propoxyphene and combination product propoxyphene/aspirin/caffeine, respectively in Y2007



Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, January 30, 2009

Total number of patients receiving a prescription for combination product propoxyphene/APAP by age from U.S. outpatient retail pharmacies, Years 2002-2007 and YTD/Oct 2008

SDI Vector One®: Total Patient Tracker (TPT), Extracted 1/2009




- 3.4 million patients aged 45-64 years received Rx for propoxyphene/APAP in Y2007 and over 3 million patients each aged 18-44 years and 65 years and older
- 28% decrease in number of patients aged 18-44 years receiving Rx between Y2002 and Y2007, 12% decrease in patients aged 45-64 years and 8% decrease in patients aged 65 years and greater



Total number of prescriptions dispensed for propoxyphene/APAP products by top 15 prescribing specialties from U.S. outpatient retail pharmacies, Years 1998-2007 and YTD/Oct 2008

SDI Vector, One®: National (VONA), Extracted 1/2009



- Leading prescribers in Y2007: General Practice* 6.3 million Rx (29%), Internal Medicine 4.2 million Rx (19%), Orthopedic Surgery 1.9 million Rx (9%)

*Family Medicine, Osteopathic Medicine, General Practice



Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, January 30, 2009

Dispensing characteristics for propoxyphene/APAP products from U.S. office-based physicians, Year 2007

‡SDI Physician Drug and Diagnosis Audit (PDDA), Extracted 1/2009

- Frequency of Duration of Use‡
 - Age 0-17 years: 0-7 days (70%)
 - Age 18-44 years: 0-7 days (54%)
 - Age 45-64 years: 0-7 days (35%)
 - Age 65+ years: 0-7 days (37%)



Prescription type for propoxyphene products by new, continuing, and add-switch parameters, Year 2007

SDI Vector One®: National (VONA). Extracted 1/2009

- **Propoxyphene/APAP**
 - **New: 58% no previous Rx within past 3 months**
 - **Continuing: 41% had Rx within past 3 months**
 - **Switch/Add-on: <1% from another pain treatment product within past 3 months**

- **Propoxyphene**
 - **New: 44% no previous Rx within past 3 months**
 - **Continuing: 55% had Rx within past 3 months**



Summary of Use for propoxyphene Products, Year 2007...

- Decline in dispensed prescriptions and number of patients for propoxyphene products for all age groups
 - Largest decrease in use seen in age 18-44 category
- Propoxyphene/APAP:
 - 21.8 million Rx and 9.7 million patients
 - 8.3 million Rx and 3 million patients elderly age 65 years and greater
 - 8.2 million Rx and 3.4 million patients aged 45-64 years
- Leading prescribers: GP(29%), Internists (19%), Orthopedic Surgeons (9%)



...Summary of Use for propoxyphene Products, Year 2007

- Most common duration of use as mentioned by office-based physicians
 - 0-7 days for all age groups
- ~58% of new Rx dispensed to those had no previous Rx for propoxyphene/APAP product within past 3 months
- ~55% of new Rx had previous Rx for propoxyphene



Backup Slide



Anesthetic and Life Support Drugs and Drug Safety and
Risk Management Advisory Committees,
January 30, 2009

Total number of prescriptions dispensed for hydrocodone, oxycodone, propoxyphene, and methadone products from U.S. outpatient retail pharmacies, Years 2004 – 2007

SDI Vector One®: National (VONA). Extracted 1/2009

